Document is current

Article History

Received: 13 April 2024

Accepted: 16 August 2024

First Online: 29 August 2024

Declarations

:

: All animal experiments were approved by the Animal Care and Use Committee of Jiangsu Institute of Nuclear Medicine and conducted in compliance with institutional guidelines (Approved number: JSINM-2023-061). Postmortem human brain tissues from control and PD patient subjects were obtained from the Chinese Brain Bank Center, with experiments approved by the Ethics, Science and Technology Committee of Central South University (Committee’s reference number: 2022-scuec-039). The use of human postmortem brain tissues was also approved by the ethics committee of our institute (Approved number: YLK-202329), and all procedures were in accordance with ethical standards. The study was carried out in compliance with the ARRIVE guidelines, and all methods adhered to relevant guidelines and regulations.

: All reagents and solvents used in the study were purchased from reputable suppliers such as Sigma-Aldrich, Cayman Chemistry Company (USA), ABX (Germany), J&K Scientific (China), or Aladdin (China) and were used without further purification. Sep-Pak C18 cartridge and Sep-Pak Light QMA used during radiosynthesis were obtained from Waters (Milford, MA, USA).

: Male Sprague-Dawley (SD) rats weighing 250–300 g were purchased from Cavens Laboratory Animal Co., Ltd. (Jiangsu, China), and were housed following the Chinese Guidelines for Animal Research. Postmortem human brain tissues from control and PD patient subjects were obtained from the Chinese Brain Bank Center. Mouse anti-tyrosine hydroxylase (TH antibody) was a commercial product of Sigma Corporation with the code T2928.

: Not applicable.

: The authors declare that they have no competing interests.

: The authors declare that they have no conflict of interest.